Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ("Cosmos Health" or the “Company”) , a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical S.A., the product’s exclusive distributor in Greece.

Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and product release, in accordance with applicable regulatory requirements.

PathMuscle is an advanced generic pharmaceutical product formulated as a fixed-dose combination of thiocolchicoside, a centrally acting muscle relaxant, and paracetamol (acetaminophen), an analgesic and antipyretic agent. The combination is designed to address musculoskeletal conditions by providing both muscle-relaxant activity and pain relief within a single dosage form.

PathMuscle is approved in multiple oral presentations, including film-coated tablets containing thiocolchicoside 2 mg and paracetamol 500 mg, supplied in 30-tablet Alu/PVC blister packs, as well as soluble tablets containing thiocolchicoside 4 mg and paracetamol 1,000 mg, supplied in 20-tablet Alu/PVC blister packs, and is indicated for the symptomatic treatment of painful muscle spasms associated with acute musculoskeletal disorders.

The product will be distributed and commercially promoted in the Greek market by Libytec Pharmaceutical S.A., with the agreement providing for firm minimum committed production volumes of 591,500 units and expected cumulative production volumes over a five-year period anticipated to exceed 1.2 million units, subject to market demand and commercial performance.

The agreement reflects Cosmos Health’s vertically integrated pharmaceutical manufacturing capabilities and is expected to support improved capacity utilization and enhanced revenue visibility across its pharmaceutical manufacturing operations.

Greg Siokas, CEO of Cosmos Health, stated: “This agreement supports our strategic focus on expanding pharmaceutical manufacturing through long-term, volume-backed collaborations. By assuming full responsibility for the end-to-end production of PathMuscle, Cosmos Health demonstrates its operational strength, regulatory expertise, and ability to deliver reliable, scalable manufacturing solutions. We believe this collaboration enhances production visibility and reinforces our position as a trusted manufacturing partner in the European pharmaceutical market.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at, , , , , as well as and .

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:

BDG Communications